Etzer Darout
Stock Analyst at Barclays
(4.52)
# 241
Out of 5,173 analysts
170
Total ratings
50.35%
Success rate
27.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Overweight | $113 → $119 | $98.54 | +20.76% | 7 | Mar 19, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $16 | $4.46 | +258.74% | 15 | Mar 19, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Overweight | $48 → $50 | $41.56 | +20.31% | 2 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Outperform | $143 → $128 | $88.41 | +44.78% | 5 | Mar 11, 2026 | |
| MGNX MacroGenics | Maintains: Overweight | $3 → $4 | $2.92 | +36.99% | 11 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $50 → $70 | $43.66 | +60.33% | 10 | Mar 4, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $78 → $79 | $62.72 | +25.96% | 5 | Mar 4, 2026 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $7 | $2.56 | +173.44% | 7 | Feb 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Overweight | $224 | $182.32 | +22.86% | 1 | Feb 27, 2026 | |
| XNCR Xencor | Maintains: Overweight | $26 → $27 | $12.05 | +124.07% | 9 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $8.84 | +239.37% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $3.63 | +203.03% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $117 | $90.45 | +29.35% | 3 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $41 → $44 | $41.41 | +6.25% | 6 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $119 → $133 | $76.96 | +72.82% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $13.75 | +103.64% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.90 | +108.63% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $31.80 | -24.53% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.32 | +74.42% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $15.60 | +15.38% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $49.61 | +12.88% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $24.09 | +45.29% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $8.32 | +236.54% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.60 | +1,594.44% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $56.26 | +122.18% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $115.42 | +23.03% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.08 | +113.82% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $6.76 | -55.62% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $14.69 | +138.26% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.19 | +5,194.12% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.60 | +1,587.50% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $96.43 | +38.96% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $25.68 | +86.92% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $148.09 | -18.97% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.15 | +421.74% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $184.07 | -55.45% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.09 | +273.28% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $306.66 | -44.56% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $89.43 | -57.51% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.58 | +1,352.51% | 1 | Mar 28, 2018 |
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $113 → $119
Current: $98.54
Upside: +20.76%
CytomX Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $10 → $16
Current: $4.46
Upside: +258.74%
Oruka Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $48 → $50
Current: $41.56
Upside: +20.31%
BioNTech SE
Mar 11, 2026
Maintains: Outperform
Price Target: $143 → $128
Current: $88.41
Upside: +44.78%
MacroGenics
Mar 10, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.92
Upside: +36.99%
Scholar Rock Holding
Mar 4, 2026
Maintains: Outperform
Price Target: $50 → $70
Current: $43.66
Upside: +60.33%
AnaptysBio
Mar 4, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $62.72
Upside: +25.96%
C4 Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.56
Upside: +173.44%
Jazz Pharmaceuticals
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $182.32
Upside: +22.86%
Xencor
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.05
Upside: +124.07%
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $8.84
Upside: +239.37%
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.63
Upside: +203.03%
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $90.45
Upside: +29.35%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $41.41
Upside: +6.25%
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $76.96
Upside: +72.82%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $13.75
Upside: +103.64%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.90
Upside: +108.63%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $31.80
Upside: -24.53%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.32
Upside: +74.42%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $15.60
Upside: +15.38%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $49.61
Upside: +12.88%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $24.09
Upside: +45.29%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $8.32
Upside: +236.54%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.60
Upside: +1,594.44%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $56.26
Upside: +122.18%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $115.42
Upside: +23.03%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.08
Upside: +113.82%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $6.76
Upside: -55.62%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $14.69
Upside: +138.26%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.19
Upside: +5,194.12%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.60
Upside: +1,587.50%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $96.43
Upside: +38.96%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $25.68
Upside: +86.92%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $148.09
Upside: -18.97%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.15
Upside: +421.74%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $184.07
Upside: -55.45%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.09
Upside: +273.28%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $306.66
Upside: -44.56%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $89.43
Upside: -57.51%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.58
Upside: +1,352.51%